EP1438323A4 - ADJUVOUS MENINGOCOCCUS COMPOSITIONS - Google Patents

ADJUVOUS MENINGOCOCCUS COMPOSITIONS

Info

Publication number
EP1438323A4
EP1438323A4 EP02800481A EP02800481A EP1438323A4 EP 1438323 A4 EP1438323 A4 EP 1438323A4 EP 02800481 A EP02800481 A EP 02800481A EP 02800481 A EP02800481 A EP 02800481A EP 1438323 A4 EP1438323 A4 EP 1438323A4
Authority
EP
European Patent Office
Prior art keywords
meningococcus
adjuvanted
compositions
meningococcus compositions
adjuvanted meningococcus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02800481A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1438323A2 (en
Inventor
Derek O'hagan
Nicholas Valiante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/010869 external-priority patent/WO2002080648A2/en
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of EP1438323A2 publication Critical patent/EP1438323A2/en
Publication of EP1438323A4 publication Critical patent/EP1438323A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EP02800481A 2001-10-03 2002-10-03 ADJUVOUS MENINGOCOCCUS COMPOSITIONS Withdrawn EP1438323A4 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US254438 1988-10-06
US32692901P 2001-10-03 2001-10-03
US326929P 2001-10-03
PCT/US2002/010869 WO2002080648A2 (en) 2001-04-05 2002-04-05 Mucosal boosting following parenteral priming
WOPCT/US02/10869 2002-04-05
US37354702P 2002-04-17 2002-04-17
US373547P 2002-04-17
US38067702P 2002-05-13 2002-05-13
US380677P 2002-05-13
US25443802A 2002-09-24 2002-09-24
US0230423 2002-09-24
WOPCT/US02/30423 2002-09-24
PCT/US2002/031726 WO2003028661A2 (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions

Publications (2)

Publication Number Publication Date
EP1438323A2 EP1438323A2 (en) 2004-07-21
EP1438323A4 true EP1438323A4 (en) 2007-08-01

Family

ID=32601151

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02800481A Withdrawn EP1438323A4 (en) 2001-10-03 2002-10-03 ADJUVOUS MENINGOCOCCUS COMPOSITIONS

Country Status (8)

Country Link
EP (1) EP1438323A4 (pt)
JP (1) JP4522699B2 (pt)
CN (1) CN100354297C (pt)
AU (1) AU2002334844B2 (pt)
BR (1) BR0213119A (pt)
CA (1) CA2462646C (pt)
NZ (1) NZ532274A (pt)
WO (1) WO2003028661A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
SI2255826T1 (sl) * 2002-08-02 2016-07-29 Glaxosmithkline Biologicals S.A. Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
JP2007523173A (ja) * 2004-02-20 2007-08-16 イデラ ファーマシューティカルズ インコーポレイテッド 修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答
CA2588089C (en) * 2004-11-15 2015-06-23 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
WO2006081576A2 (en) 2005-01-28 2006-08-03 Galenbio, Inc. Immunologically active compositions
ATE438385T1 (de) * 2005-03-02 2009-08-15 Secr Defence Pharmazeutische zusammensetzung
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
CN101559225B (zh) * 2008-04-18 2012-07-11 北京生物制品研究所 脑膜炎球菌疫苗
PL2863942T3 (pl) * 2012-06-21 2019-12-31 Northwestern University Cząstki sprzężone z peptydem

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2671261A1 (en) * 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
BR9906927A (pt) * 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
NZ541361A (en) * 1998-05-01 2008-04-30 Inst Genomic Research Neisseria meningitidis antigens and compositions relating to SEQ ID Nos:2916, 2918 and 2920
JP4601168B2 (ja) * 1998-07-29 2010-12-22 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 吸着表面を有する微小粒子、それを作製する方法、およびその使用
EP1144998A3 (en) * 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
AU2875700A (en) * 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
MXPA01010924A (es) * 1999-04-30 2002-05-06 Chiron Spa Antigenos de neisseria conservados.
BR0108711A (pt) * 2000-02-28 2004-06-22 Chiron Spa Expressão heteróloga de proteìnas de neisseria

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
O'HAGAN D T ET AL: "POLY(LACTIDE-CO-GLYCOLIDE) MICROPARTICLES FOR THE DEVELOPMENT OF SINGLE-DOSE CONTROLLED-RELEASE VACCINES", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 32, 1998, pages 225 - 246, XP000944990, ISSN: 0169-409X *
SINGH M ET AL: "ADVANCES IN VACCINE ADJUVANTS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 17, no. 11, November 1999 (1999-11-01), pages 1075 - 1081, XP000941305, ISSN: 1087-0156 *
SINGH M ET AL: "Cationic microparticles are an effective delivery system for immunie stimulatory CpG DNA", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 18, no. 10, October 2001 (2001-10-01), pages 1476 - 1479, XP002976979, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
CA2462646A1 (en) 2003-04-10
JP4522699B2 (ja) 2010-08-11
BR0213119A (pt) 2004-12-28
EP1438323A2 (en) 2004-07-21
CA2462646C (en) 2013-02-12
JP2005526697A (ja) 2005-09-08
AU2002334844B8 (en) 2003-04-14
WO2003028661A3 (en) 2003-10-09
AU2002334844B2 (en) 2007-08-02
CN1599746A (zh) 2005-03-23
CN100354297C (zh) 2007-12-12
WO2003028661A2 (en) 2003-04-10
NZ532274A (en) 2006-02-24

Similar Documents

Publication Publication Date Title
IL227966A0 (en) Vaccination kit
EP1438074A4 (en) ADJUVANT COMPOSITIONS
GB0103170D0 (en) Vaccine composition
GB0103171D0 (en) Vaccine composition
HUP0301413A3 (en) Vaccine compositions
PL368370A1 (en) Glyphosate composition
IL188834A0 (en) Novel vaccine composition
GB0129007D0 (en) Adjuvanted antigenic meningococcal compositions
HUP0303942A3 (en) Novel vaccine composition
EP1438323A4 (en) ADJUVOUS MENINGOCOCCUS COMPOSITIONS
HUP0400174A2 (en) Lipid-polymer-conjugates compositions
PT1368456E (pt) Composições de vacina anti-bacteriana
GB0126266D0 (en) Anthrax antigenic compositions
GB0126244D0 (en) Oral compositions
GB0200763D0 (en) Compositions
HUP0600303A2 (en) Pentafluorpropane based compositions
EG23126A (en) Novel fungicial compositions
ZA200401211B (en) Antigenic compositions
GB0105622D0 (en) Compositions
GB0114532D0 (en) Novel compositions
GB0000438D0 (en) Dental compositions
GB0103328D0 (en) Compositions
GB0018230D0 (en) Dental compositions
GB0112345D0 (en) Compositions
GB0101392D0 (en) Compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040420

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20070704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/385 20060101ALI20070628BHEP

Ipc: A61K 39/095 20060101ALI20070628BHEP

Ipc: A61K 39/02 20060101AFI20070628BHEP

17Q First examination report despatched

Effective date: 20101020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140501